ChromoGenics resolves on a directed issue of shares by set-off
The board of directors of ChromoGenics AB (publ), corp. reg. no. 556630–1809, authorised by the general meeting on the 18 June 2019 (for 20,000,000 shares) and on the 7 August 2019 (for the remaining 7,627,679 shares), has resolved on a directed issue of shares by set-off of maximum 27,627,679 new shares (the “Set-off issue”) to the German company Hörmann-Verwertungen GmbH & Co. KG from which ChromoGenics acquired machinery in May 2019.
The subscription price is stipulated in the agreement regarding acquisition of machinery previously entered into with the subscriber. The new shares are issued at a subscription price of SEK 0.56 per share, which corresponds to the average rate for the company's share during a trading period defined in the machinery purchase agreement. The new shares will be paid by set-off of the subscriber’s claim against the company (in accordance with the agreement regarding acquisition of machinery). Subscription shall be made not later than 13 September 2019. Through the Set-off issue, the company’s share capital will be increased by maximum SEK 5,525,536.09.
The reason for the deviation from the shareholders pre-emption right is that ChromoGenics shall to be able to fulfil its obligations under the agreement entered with Hörmann-Vertungen GmbH & Co. KG in May 2019 regarding the acquisition of machinery.
Jerker Lundgren, CEO
Lars Ericsson, CFO and Head of Communications
Tel: +46 (0)18 430 0430
Every care has been taken in the translation of this document. However, in the event of discrepancies, the Swedish version will supersede the English translation.
ChromoGenics offers dynamic glass with controllable heat- and light transmission and static glass with world leading performance. The company’s unique technology ConverLight® provides sustainable solar control for increased indoor comfort and energy efficiency. ConverLight also contributes to Green Building certifications. In 2016 the company started commercial sales to real estate projects in Scandinavia.
ChromoGenics is located in Uppsala, Sweden, and the technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, e-mail: firstname.lastname@example.org, tel.: +46 (0) 8 503 000 50 www.chromogenics.com